Ravulizumab: A New Treatment Option for PNH?
Austin Kulasekararaj, MD, MBBS, MRCP, FRCPath, shares results from a phase III study comparing ravulizumab with eculizumab in patients with paroxysmal nocturnal hemoglobinuria.
A Rapid, Inexpensive Screening Test for Sickle Cell Disease in Uganda
Erik Serrao, PhD, discusses the HemoTypeSC test, which provides a rapid, cost-effective screening method for sickle cell disease in newborns living in limited-resource settings.
Elotuzumab Combination Prevents Progression from Smoldering to Symptomatic Myeloma
Irene Ghobrial, MD, shares results from a phase II trial, in which 84 percent of patients with high-risk smoldering multiple myeloma responded to treatment...
PERIOP 2: Do Patients at High Risk for Arterial Thromboembolism Need LMWH Bridging?
Michael Kovacs, MD, discusses results from the PERIOP 2 trial, which found that post-procedure bridging with low-molecular weight heparin during warfarin interruption offered no...
A New Personalized Risk-Stratification Model for Myelodysplastic Syndromes
Dr. Nazha discusses a new tool for the risk-stratification of patients with myelodysplastic syndromes, which outperformed traditional risk models.
Evaluating a Venetoclax and Carfilzomib Combination in Myeloma
Luciano Costa, MD, PhD, shares findings from a phase II study, in which the combination appeared tolerable and effective in patients with relapsed/refractory myeloma.
Is Luspatercept a New Option for Patients With MDS?
Dr. List discusses results from the MEDALIST trial in patients with transfusion-dependent myelodysplastic syndromes, which were presented as a plenary abstract at the 2018...
Ibrutinib Outperforms Chemoimmunotherapy in CLL
Dr. Woyach shares findings from her plenary abstract, in which ibrutinib improved survival outcomes in older patients with chronic lymphocytic leukemia, compared with a...
Four or Six Cycles of CHOP in Younger DLBCL Patients?
Viola Poeschel, MD, discusses results from the Flyer trial, which showed that younger, fit patients with diffuse large B-cell lymphoma can be treated with...
AMG 330 Takes a BiTE out of Relapsed/Refractory AML
Farhad Ravandi-Kashani, MD, discusses results from the first-in-human trial showing the bispecific T-cell engager antibody was tolerable in patients with previously treated acute myeloid leukemia.
Current Issue
March 2019, Volume 5, Issue 4
This issue features a look at the misconceptions about travel-associated blood clots, the treatment of young patients with myeloma, and more.
